Plasma Fractionation Market Increasing Role of Biotech and Pharma Companies | 2032 Forecast

The plasma fractionation market revolves around the process of separating blood plasma into its therapeutic components—such as immunoglobulins, clotting factors, albumin, and protease inhibitors—for treating a variety of conditions like immune deficiencies, bleeding disorders, and neurological and pulmonary diseases. The market is expanding steadily, driven by rising prevalence of autoimmune and hematological disorders, growing geriatric populations, and increased healthcare access globally. North America holds a dominant position due to strong collection networks and advanced infrastructure, while Asia-Pacific is emerging rapidly thanks to expanding plasma collection and manufacturing capabilities. Continuing challenges include high cost, complex manufacturing requirements, supply limitations of donor plasma, and competition from recombinant alternatives.

According to Fortune Business Insights, the global plasma fractionation market was valued at USD 37.31 billion in 2024 and is projected to grow from USD 40.27 billion in 2025 to USD 72.45 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.8% during the forecast period. In 2024, North America dominated the market with a 56.18% share.

Top Companies in the Market

• CSL Behring (CSL) (U.S.)

• Grifols, S.A (Spain)

• Takeda Pharmaceutical Company Limited (Japan)

• Kedrion S.p.A (Italy)

• Octapharma (Switzerland)

• ADMA Biologics, Inc. (U.S.)

• Sartorius AG (Germany)

• LFB (France)

Market Coverage & Competitive Landscape

This report provides comprehensive intelligence on the plasma fractionation industry, including:

• Detailed market size and forecasts (2025–2032)

• Segment analysis by end-user, product, and application

• Regional breakdown across major geographies

• Competitive landscape highlighting key players and strategic initiatives

• Market drivers, restraints, and emerging trends

Leading companies such as CSL Behring, Grifols, Takeda, Octapharma, Kedrion, and others are driving the competitive dynamics through capacity expansion, partnerships, and regulatory approvals

Key Industry Development

In July 2024, Kedrion S.p.A. announced a framework for a long-term agreement with Biotest AG for the full commercialization and distribution of the immunoglobulin therapy Yimmugo in the U.S. market.

Market Drivers

Several factors are driving the growth of the plasma fractionation market:

• Rising prevalence of chronic and immune-related diseases, including autoimmune and bleeding disorders, which increases demand for plasma-derived therapies.

• Advancements in plasma fractionation technologies improving efficiency and output.

• Growing demand for immunoglobulin, albumin, coagulation factors, and protease inhibitors to treat conditions such as immune deficiencies and trauma-related shock.

Restraints

• The availability and safety of recombinant therapies pose a competitive challenge to plasma-derived options by offering alternatives with lower risk of blood-borne transmissions.

• High production costs—entailing sophisticated equipment and skilled operations—limit affordability and scalability, constraining market growth.

Market Segments

• Product Segments: Immunoglobulin segment leads market share, due to widespread usage in treating immunodeficiency and autoimmune conditions.

• Application Segments: Immunology & Neurology dominate. Critical Care ranks third, propelled by demand for coagulation therapies following trauma.

• End-user Segments: Hospitals & Clinics hold the highest revenue share; Clinical Research Laboratories follow closely, driven by R&D in rare disease therapeutics. Others (like academic and treatment centers) show slower growth.

Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614 

Market Regional Insights

North America dominated with USD 20.96 billion in 2024, accounting for 56.18% of the global market. This dominance stems from robust healthcare infrastructure, advanced plasma collection networks, and strong presence of major players.

Europe held the second-largest share, supported by greater awareness of immunodeficiency conditions, plasma collection initiatives, and strategic acquisitions such as Kedrion’s expansion in the Czech Republic.

Asia Pacific is gaining momentum driven by growing pharmaceutical investments, rising chronic disease burden, and improved healthcare access. Notable moves include Plasma Gen Biosciences’ facility in Bangalore (May 2023).

Latin America, Middle East & Africa show relatively modest growth, though increasing autoimmune disease prevalence and partnerships—for instance, GC BioPharma’s USD 90.48 million IVIG-SN supply contract with Brazil’s Blau Farmacêutica—point toward rising opportunities.

Future Market Scope

The plasma fractionation market is poised for strong growth throughout the forecast period, with the following trends expected to shape its future:

• Continued expansion in the adoption of plasma-derived therapeutics to manage immune, hematological, and trauma-related conditions.

• Strengthening of infrastructure and plasma collection networks by key players to meet growing demand.

• Regulatory approvals and commercial agreements—such as Kedrion’s 2024 Yimmugo deal—supporting new product penetration and geographical expansion.

Conclusion

The plasma fractionation market is on a strong growth trajectory, with an expected jump from USD 37.31 billion in 2024 to USD 72.45 billion by 2032, growing at an 8.8% CAGR. North America remains the dominant market while hospitals and clinics drive end-user growth. Continued R&D, infrastructure expansion, and strategic alliances—which include Kedrion’s U.S. agreement—are key to future market momentum. Stakeholders across the value chain should stay informed and agile to capitalize on robust demand for plasma-derived therapies in the years to come.

About Us:

Fortune Business Insights provides expert corporate analysis and accurate data, enabling businesses of all sizes to make timely decisions. We offer customized solutions tailored to each client’s needs, helping them address unique challenges. Our goal is to empower clients with holistic market intelligence and offer granular insights into the market they operate in.

At Fortune Business Insights, we aim to highlight growth opportunities for our clients, offering insights and recommendations that help them navigate technological and market changes. Our consulting services are designed to help companies uncover hidden opportunities and address competitive challenges.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free),

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com